For only the fourth time since World War II, the U.S. midterm election flipped control of both the House and the Senate. (The ...
Colorectal cancer (CRC) remains difficult to treat, particularly after resistance to targeted therapies and immunotherapy ...
At last week’s World Congress on Pain, Kinoxis Therapeutics Pty and the University of Sydney reported data regarding their ...
China’s clinical trial advantage is beginning to reshape more than the development of Chinese drugs. Faster recruitment, lower costs and growing scientific capabilities are raising a broader question: ...
Medtronic plc revealed new data which showed that its Symplicity Spyral renal denervation (RDN) system significantly reduced blood pressure (BP) in a diverse patient population. Office systolic BP ...
Med-tech financings across all categories totaled $3.29 billion in the third quarter (Q3) of 2026, down 14.5% from $3.86 billion in Q2 and 61% from $8.54 billion in Q1, marking the lowest quarterly ...
Shares of Nurix Therapeutics Inc. (NASDAQ:NRIX) fell 37% on news that partner Sanofi SA opted to end work on SAR-448272, an oral STAT6 degrader that emerged from the companies’ 2019 agreement.
A pair of popular modalities stands at the back-end-loaded, potential $7 billion-plus deal inked by Boehringer Ingelheim GmbH and Sino Biopharmaceutical Ltd.: antibody-drug conjugates (ADCs) and ...
The publication this spring in The Lancet Respiratory Medicine of new data with Amgen Inc. and Astrazeneca plc’s Tezspire (tezepelumab) fed hopes in severe asthma, where a handful of developers are ...
Researchers are taking new steps to improve CAR T-cell therapies by better understanding their behavior and engineering them to overcome some of their limitations, from treatment failure and T-cell ...
Prostate-specific membrane antigen (PSMA) is overexpressed in primary and metastatic prostate cancer, including metastatic lesions in lymph nodes and bone, compared with normal prostate tissues. ADC ...
Highslab Therapeutics Inc. recently provided details on HL-7037, a cyclic peptide designed to selectively target glypican-3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results